Drug Profile
Research programme: immunomodulatory recombinant fusion proteins - Compugen
Alternative Names: CGEN 15001T based protein therapeutics; CGEN 15021 based protein therapeutics; CGEN 15021T; CGEN 15022 based protein therapeutics; CGEN 15031 based protein therapeutics; CGEN 15051 based protein therapeutics; CGEN 15092 based protein therapeutics; CGEN-15001 based protein therapeutics; CGEN-15052 based protein therapeutics; CGEN-15091 based protein therapeuticsLatest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Compugen
- Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Antirheumatics; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD28 antigen modulators; CD80 antigen modulators; Immunomodulators; Macrophage modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in Israel (Parenteral)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Cancer in Israel (Parenteral)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Multiple-sclerosis in Israel (Parenteral)